The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
Suzi B ClaflinJulie A CampbellDeborah F MasonTomas KalincikSteve Simpson YapRichard NormanHelmut ButzkuevenWilliam M CarrollAndrew J PalmerC Leigh BlizzardIngrid van der MeiBruce V TaylorPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
This study provides evidence for the impact of national-level DMT policy on disability outcomes in PwMS. Where DMTs are more accessible, PwMS experienced less disability progression and improved QoL 10-20 years post-diagnosis.